Average Co-Inventor Count = 2.83
ph-index = 17
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Merck Sharp + Dohme Corp. (80 from 2,405 patents)
2. Novira Therapeutics, Inc. (20 from 44 patents)
3. Sloan-kettering Institute for Cancer Research (8 from 512 patents)
4. Janssen Biotech, Inc. (6 from 410 patents)
5. Yuhan Corporation (4 from 93 patents)
6. Merck + Co., Inc. (3 from 4,770 patents)
7. Other (1 from 832,843 patents)
8. Janssen Sciences Ireland Unlimited Company (60 patents)
9. Merck Sharp & Dohme LLC (6 patents)
118 patents:
1. 12258327 - 5-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors
2. 12258328 - 6-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors
3. 11981658 - Substituted aminopyridine compounds as EGFR inhibitors
4. 11945798 - Substituted aminopyridine compounds as EGFR inhibitors
5. 11753393 - Dihydroorotate dehydrogenase inhibitors
6. 11505536 - Dihydroorotate dehydrogenase inhibitors
7. 10987359 - Oxadiazepinone derivatives and methods of treating hepatitis B infections
8. 10975077 - Diazepinone derivatives and their use in the treatment of hepatitis B infections
9. 10556904 - Derivatives and methods of treating hepatitis B infections
10. 10544141 - Derivatives and methods of treating hepatitis B infections
11. 10537580 - Azocane and azonane derivatives and methods of treating hepatitis B infections
12. 10538519 - Derivatives and methods of treating hepatitis B infections
13. 10526336 - Fused heteroaryl derivatives as orexin receptor antagonists
14. 10435398 - Oxazole orexin receptor antagonists
15. 10392349 - Azepane derivatives and methods of treating hepatitis B infections